Clinical trials: Lung Volume
Monitoring of Regional Distribution of Ventilation, Monitoring of Lung Volume
Prospective, Open, Non-interventional Study to Assess the Ability of an Electrical Impedance Tomograph (PlumoVista 500)
This observational PMCF study will be conducted to generate and gather clinical data from the intended target population of pediatric patients.
- Trial name
- PV500ped (NCT04873999)
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Drägerwerk AG & Co. KGaA
Pulmonary Arterial Hypertension
Assessmet of Patients With PAH Right Ventricular Volume
The primary endpoint of this study is the percent difference between the VentriPoint Medical System (VMS) and cMRI for estimating the end diastolic and end systolic right ventricular volumes (RVEDV and RVESV) in subjects with…
- Trial name
- NCT01557582
- Testing
- Ventripoint Medical System
- Where
- 7 sites in United States, Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VentriPoint Diagnostics Ltd.
COPD
Comparing Pressure Based and Dilution Based Total Lung Capacity Measurements in COPD Patients for Lung Function Diagnostics
Total Lung Capacity (TLC) of the lungs can be determined using a pressure based method (i.e. by body plethysmography) or it can be determined using a dilution based method (i.e.
- Trial name
- NCT04531293
- Testing
- Respiratory Analysis System
- Where
- Switzerland
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ndd Medizintechnik AG
Asthma
Inspiratory Flow Using the Osmohaler
The OsmohalerTM is a registered device in Australia. It is used to deliver a dry powder a commercial preparation of mannitol registered as AridolTM to test if a person has irritable airways such as active asthma.
- Trial name
- NCT00531414
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Syntara
Pulmonary Disease, Chronic Obstructive
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive…
- Trial name
- ECLIPSE (NCT00292552)
- Testing
- Novel endpoint determination
- Where
- 44 sites in United States, Bulgaria and 10 more
- Volunteers
- 2,747 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Emphysema
A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)
Use of the Chartis® Assessment System prior to EBV Treatment
- Trial name
- NCT01101958
- Testing
- Chartis System, Endobronchial Valve (EBV) Treatment
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pulmonx Corporation
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
This study is designed to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics (proof of concept) of QBW251 in healthy subjects and cystic fibrosis patients following single and multiple doses.
- Trial name
- NCT02190604
- Testing
- QBW251
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals